CURRENT OPINION IN PULMONARY MEDICINE呼吸医学新见
CURRENT OPINION IN PULMONARY MEDICINE(英文缩写 CURR OPIN PULM MED),ISSN 1070-5287,eISSN 1531-6971,中文译名:呼吸医学新见 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.868 | Q4 |
| 2022 | 3.300 | Q3 |
| 2023 | 2.800 | Q2 |
| 2024 | 2.800 | Q2 |
| 2025 | 2.700 | Q2 |
CURRENT OPINION IN PULMONARY MEDICINE 最新收录文献
-
1. Parsonage-turner syndrome: a pulmonologist's guide to the forgotten diaphragm.
PMID:日期:2026-09-18Parsonage-Turner syndrome (PTS), or neuralgic amyotrophy, is framed as a shoulder disorder owned by neurology, and that framing has cost pulmonologists patients. Roughly 1 in 13 develops phrenic neuropathy, and many patients referred for unexplained dyspnea, orthopnea, or rapid eye movement (REM)-predominant sleep-disordered breathing have an undiagnosed, treatable inflammatory neuropathy. This review reframes PTS for pulmonologists. Three developments have reshaped practice. High-resolution neuromuscular ultrasound and MR neurography now identify the hourglass constrictions and fascicular entwinement of PTS at the bedside, including in the phrenic nerve. COVID-19 infection and SARS-CoV-2 vaccination produced a global cluster, expanding the phenotype toward bilateral and respiratory-predominant disease. Large Dutch cohort data have replaced anecdote with structure: roughly 60% of patients with phrenic involvement recover meaningfully within 2 years, while the remainder respond best to early noninvasive ventilation and, in refractory cases, diaphragmatic plication. Every pulmonologist evaluating unexplained dyspnea, disproportionate orthopnea, or REM-predominant hypopneas should ask one question: was there severe shoulder or neck pain in the weeks before the breathing changed? If yes, screen with upright and supine spirometry and diaphragm ultrasound. The diagnosis is reachable in a single visit, the immunomodulation window is short, and the cost of missing it is years of avoidable disability.
-
2. Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis.
PMID:日期:2026-09-18Bronchiectasis from cystic fibrosis and noncystic fibrosis causes include a spectrum of chronic suppurative airway conditions that share key pathophysiologic mechanisms but differ substantially in genetic basis, epidemiology, and clinical course. Recent therapeutic advances, particularly highly effective CFTR modulators in cystic fibrosis and emerging anti-inflammatory therapies in bronchiectasis, have reshaped disease management and prompted re-evaluation of treatment paradigms, outcome measures, and approaches to long-term monitoring. In cystic fibrosis, highly effective CFTR modulator therapy, including elexacaftor/tezacaftor/ivacaftor and the recently approved once daily vanzacaftor/tezacaftor/deutivacaftor, has produced sustained increase in lung function, reduced frequency of pulmonary exacerbations, and improved quality of life, while highlighting the limitations of FEV1 as a sole future marker of treatment response. In noncystic fibrosis bronchiectasis, the phase 3 ASPEN trial demonstrated that brensocatib, a dipeptidyl peptidase-1 inhibitor, significantly reduces exacerbation frequency and slows lung function decline at the higher dose, representing a potential disease-modifying therapy. Emerging evidence also underscores the prognostic importance of comorbidities and disease modifiers, including Pseudomonas aeruginosa and gastroesophageal reflux disease. Management of all forms of bronchiectasis is increasingly shifting toward individualized, endotype-directed care. Integration of disease-modifying therapies, systematic assessment of comorbidities, validated severity stratification tools, and patient-reported outcomes will be essential to optimizing long-term clinical outcomes and advancing precision medicine approaches across this heterogeneous disease spectrum.
-
3. Eosinophils in bronchiectasis.
PMID:日期:2026-09-18Bronchiectasis has traditionally been viewed as a predominantly neutrophil-driven airway disease. Recognition of eosinophilic inflammation in a substantial subset of patients has challenged this paradigm. This review summarizes emerging evidence regarding its pathogenesis, clinical significance, and therapeutic implications. Eosinophilic bronchiectasis is identified using blood or sputum eosinophilia, although optimal biomarkers and thresholds are unclear. Eosinophilic inflammation occurs in bronchiectasis and overlapping disease states characterized by type 2 immune activation, including asthma, allergic bronchopulmonary aspergillosis, and cystic fibrosis, complicating diagnosis but potentially informing disease severity, prognosis, and treatment options. Evidence for targeted therapies is limited to largely observational data. Patients with elevated eosinophil counts may derive greater benefit from inhaled corticosteroids. Early studies of biologics appear promising, particularly in patients with coexisting ABPA or asthma, although their benefit in eosinophilic bronchiectasis independent of these conditions remains uncertain. Eosinophilic bronchiectasis represents a distinct inflammatory endotype that may enable a more personalized approach to disease management. Future studies should identify clinically relevant biomarkers to standardize its definition, clarify its relationship with overlapping type 2 airway diseases, and guide the use of inhaled corticosteroids and biologics.
-
4. The effect of mask choice on adherence to positive airway pressure treatment for obstructive sleep apnea in adults.
PMID:日期:2026-09-18Mask choice is among the few modifiable determinants of positive airway pressure (PAP) effectiveness in adults with obstructive sleep apnea OSA), yet selection is often shaped by convention, habit, or local inventory rather than evidence. We review recent literature, emphasizing studies from the past 18 months and incorporating foundational mechanistic and outcomes studies that should influence prescribing choices. Population-scale telemonitoring analyses confirm that nasal interfaces outperform oronasal masks on adherence, required pressure, residual apnea-hypopnea index (AHI), and unintentional leak. Switching patients from an oronasal to a nasal mask can increase adherence by up to 77%. Drug-induced sleep endoscopy with PAP, cine MRI, and sealed-compartment physiology suggest three main mechanisms for these observations: oral pressure transmission without oral airflow, posterior tongue and mandibular displacement, and increased pharyngeal collapsibility. Mandibular jaw-movement signals allow leak phenotyping that distinguishes mask-seal failure from mouth opening, supporting targeted intervention rather than reflexive interface change. Current evidence supports a nasal-first prescribing strategy with structured early follow-up using telemonitored adherence, residual AHI, and leak waveform data. Oronasal masks should be reserved for documented and structured nasal-trial failure rather than selected on the basis of self-reported breathing route.
-
5. Bronchiectasis in immunodeficiency.
PMID:日期:2026-09-18As the field of bronchiectasis continues to advance, so does the recognition of undiagnosed immunodeficiency as a potential contributor. This review aims to highlight what is currently known about bronchiectasis in immunodeficiency as well as explore future therapeutics and needs. Guidelines emphasize the need for evaluation for underlying immunodeficiency in patients with known bronchiectasis. Despite this known association, evaluation continues to be variable in clinical practice resulting in potentially missed therapeutic options, such as immunoglobulin replacement therapy in the setting of immunodeficiency. While the mainstay treatment for those with bronchiectasis and immunodeficiency continues to be immunoglobulin replacement therapy and prophylactic antibiotics, the future is hopeful with more directed therapy for the underlying pathophysiology of bronchiectasis with targeted agents such as brensocatib. This review highlights the need for ongoing research to improve detection of bronchiectasis in immunodeficiency and include patients with immunodeficiency and bronchiectasis in trial designs for therapeutics in bronchiectasis.
-
6. State of the art: practical evaluation and management of tuberculous pleural effusion.
PMID:日期:2026-09-17Tuberculous pleuritis (TBP) is one of the most common causes of new-onset pleural effusion, particularly in tuberculosis-endemic regions. This review discusses recent advances in the diagnosis and practical management of TBP, with an emphasis on integrating biomarkers, molecular tests, imaging and pleural tissue sampling into context-specific workflows. The clinical and radiological features of TBP are highly heterogeneous. Certain imaging patterns can help distinguish TBP from other benign or malignant effusions, but they are not fully diagnostic. The diagnostic accuracy of conventional pleural fluid microbiology is limited by the paucibacillary nature of TBP, prompting greater use of pleural biopsy and medical thoracoscopy, which improve microbiological and histological yield. Advanced nucleic acid amplification tests (NAATs), including Xpert MTB/RIF Ultra and emerging sequencing-based assays, have progressively increased sensitivity on pleural fluid, but wider clinical adoption is constrained by incomplete external validation, cost and limited availability. Adenosine deaminase remains the most commonly used pleural fluid biomarker. However, its optimal diagnostic thresholds are highly context-specific and may shift with changing tuberculosis incidence and age distribution. Practical diagnostic workflows now favour flexible use of biomarkers, imaging and pleural tissue sampling to maximize confirmation of TB involvement, while recognizing that patients with probable TBP treated empirically require close follow-up to document treatment response and exclude alternative diseases. Management remains centred on standard anti-tuberculosis regimens, with drainage and other interventions reserved for symptom relief or loculated disease and routine corticosteroid use is not supported by high-quality evidence. Despite advances in pleural fluid biomarkers, molecular diagnostics and pleural procedures, TBP remains challenging to diagnose reliably. Clinicians should maintain a high index of suspicion for TBP in undiagnosed exudative effusions, especially in endemic regions and adopt locally adapted workflows that combine clinical assessment, biomarkers, NAATs and early pleural tissue sampling when needed.
-
7. Disparities in sleep-disordered breathing: epidemiology, mechanisms, and pathways toward equity- a narrative review.
PMID:日期:2026-09-02Sleep-disordered breathing (SDB), encompassing obstructive sleep apnea (OSA) and related conditions, affects tens of millions of individuals in the United States and is associated with substantial cardiovascular, metabolic, and neurocognitive morbidity. However, the burden of SDB is not equally distributed across racial, ethnic, and socioeconomic groups, with significant disparities in referral, diagnosis, and treatment of these conditions within traditionally underserved populations. Racial and ethnic minority populations, most notably Black, Hispanic/Latinx, and Asian Americans, experience higher prevalence of SDB, greater severity at diagnosis, and lower rates of effective treatment compared with non-Hispanic White populations. Societal determinants including neighborhood disadvantage, occupational exposures, structural racism, and variable/suboptimal access to diagnosis and treatment propagate these inequities resulting in disparities in treatment outcomes, as exemplified by lower adherence rates to continuous positive airway pressure (CPAP) therapy in minoritized groups, even after adjustment for clinical confounders. Addressing disparities in SDB requires multilevel interventions spanning individual clinical care, health system redesign, and policy reform. Culturally adapted diagnostic pathways, community-engaged implementation strategies, and expanded insurance coverage for sleep studies and positive airway pressure therapy represent actionable near-term priorities.
-
9. Chronic pulmonary aspergillosis and sarcoidosis.
PMID:日期:2026-09-01This review addresses the intersection between chronic pulmonary aspergillosis (CPA) and sarcoidosis, a clinically important but relatively understudied association. While few new sarcoidosis-specific data have emerged, recent advances in CPA research across broader underlying conditions (particularly structural lung diseases) provide updated insights into diagnosis, antifungal therapy, and management strategies that can be extrapolated to sarcoidosis. CPA affects ~2% of sarcoidosis patients in tertiary cohorts and arises from combined structural lung damage, immune dysfunction, and environmental exposure. Diagnosis relies on integrated imaging, Aspergillus-specific immunoglobulin G, and new microbiological tools. Recent data refine therapeutic strategies regarding triazole selection, treatment duration, and salvage therapies. Management of haemoptysis relies on bronchial artery embolization, with emerging adjuncts such as local antifungal therapies and endobronchial valves. In addition, new epidemiological data have better characterized severe forms of CPA and refined estimates of mortality, highlighting a substantial disease burden. Serological markers may help predict relapse, and updated consensus criteria standardize response assessment. CPA in sarcoidosis reflects advanced fibrocystic disease with complex host-pathogen interactions. Early recognition, optimized antifungal therapy, careful adjustment of immunosuppression, and structured haemoptysis management are central to care. Prospective sarcoidosis-specific studies are still needed to refine long-term strategies.
-
10. Pragmatic approaches to improve the care of patients with sarcoidosis.
PMID:日期:2026-09-01Sarcoidosis is associated with an increasing global burden, driven by rising prevalence, severe organ involvement, treatment-related morbidity, and substantial impairment in quality of life (QoL). Despite advances in diagnostics and therapeutics, important barriers continue to limit timely, equitable, and patient-centered care. This review highlights three common challenges in sarcoidosis management and outlines pragmatic approaches to address them, using a patient-centered framework that emphasizes whether patients feel better, function better, and are able to thrive. Recent evidence confirms persistent delays in diagnosis, limited access to sarcoidosis expertise, and inequities in referral to specialized care. Growing data indicates that chronic glucocorticoid use contributes substantially to long-term morbidity, supporting glucocorticoid stewardship and earlier use of steroid-sparing therapies. In parallel, patient-reported manifestations, such as fatigue, cognitive dysfunction, dysautonomia, and small fiber neuropathy-related symptoms, are increasingly recognized as major determinants of functional impairment and health-related QoL inadequately captured by traditional objective disease markers. Recent expert recommendations emphasize practical, implementable strategies applicable across both specialist and nonspecialist settings. Improving sarcoidosis care requires a pragmatic, holistic approach that prioritizes timely diagnosis, equitable access to expertise, minimization of glucocorticoid-related harm, and systematic assessment of patient-reported outcomes. Collectively, these strategies support a patient-centered framework that evaluates treatment success not only by disease control but also by whether patients feel better, function better, and are able to thrive in the context of optimal health, meaningful social connection and contribution. This approach aligns care with patient priorities and supports individualized, shared decision-making.